Advertisement
Drug update

Sacubitril–valsartan: changing the paradigm for heart failure with reduced ejection fraction

Christopher Hayward

Figures

Abstract

Sacubitril–valsartan represents a new drug class, the angiotensin receptor–neprilysin inhibitors, that shows potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.

Article Extract

Following the recent PARADIGM-HF trial involving sacubitril–valsartan, recommendations on the optimal medical therapy for a significant proportion of patients with heart failure may be on the cusp of change.1,2 The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan has potential to replace ACE inhibitors in the treatment of selected patients with heart failure with reduced ejection fraction.

Picture credit: © Lightsource/Depositphotos.

Figures